31.08.09 19:05 Age: 193 days
Revenue for the First Half of 2009
Category: Investors
Very buoyant growth: +111%
Further intensification of activity in the United States
Marseille, 31 August 2009 - IPSOGEN (Alternext - FR0010626028 - ALIPS), a cancer ‘profiler’ that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, today announces revenue of €3.3 million for its first half to 30 June 2009.
More info
